Moderna Inc.'s rapid advancement of a vaccine candidate for COVID-19 into clinical trials may help the company establish its messenger RNA platform and advance work on other vaccines in its pipeline.
Moderna's Vaccine Portfolio Primed For Boost From Its COVID-19 Work
At its "Vaccines Day" with investors, Moderna execs tout the company's messenger RNA platform and say its portfolio of vaccine candidates has the potential to reach annual peak sales of up to $12bn.
More from COVID-19
More from Scrip
• By
Sanofi's Paul Hudson and Novartis's Vas Narasimhan claim that while Europe is home to some of the most important biopharma companies in the world, its position is in jeopardy.
• By
Paul Stoffels, the J&J research veteran who helmed Galapagos during a crucial period, will retire upon the appointment of a new CEO as the company continues its latest transformation.
• By
The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.